Pharma Faces More Probes On Generic Price Hikes in UK
As Concordia finds itself in the dock again, this time over its pricing of the essential thyroid treatment liothyronine, the UK's Competition and Markets Authority has recently opened four new investigations into "suspected abuse of dominance" concerning generics.
You may also be interested in...
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.
Concordia has announced that six more of its medicines are involved in the UK competition inquiry. One law firm says the announcement further underlines the Competition and Markets Authority’s determination to root out anticompetitive practices in the pharma area.
The UK's competition authority is keen to expose supposed pay-for-delay deals made by pharmaceutical firms, and is warning drug suppliers to think twice before attempting agreements that slow the entry of generic products onto the UK market.